As of January 2026, over 270 medications are still in short supply across the United States - a number that may seem lower than the peak of 323 in early 2024, but the reality on the ground hasn’t improved for patients or providers. These aren’t obscure drugs. They’re the ones you rely on for cancer treatment, infections, diabetes, and even basic hydration. If you’ve been told your prescription is unavailable, or your hospital switched your IV fluid to a different brand, you’re not alone. This isn’t a temporary hiccup. It’s a broken system, and it’s affecting real people every single day.
What’s Actually Running Out?
The most critical shortages are in generic sterile injectables, especially those used in hospitals. These aren’t pills you pick up at the pharmacy - they’re life-saving drugs given through IV lines. Right now, these are the most impacted:- 5% Dextrose Injection (small volume bags) - Used to treat low blood sugar and dehydration. Shortage started in February 2022, expected to last until August 2025.
- 50% Dextrose Injection - A concentrated sugar solution for emergency hypoglycemia. Shortage began in December 2021, with no resolution expected until September 2025.
- Cisplatin - A key chemotherapy drug for testicular, ovarian, and lung cancers. A 2022 FDA shutdown of an Indian manufacturing plant cut off half the U.S. supply. Hospitals now ration it, prioritizing patients with the highest chance of survival.
- Vancomycin - A last-resort antibiotic for serious infections like MRSA. Shortages have dragged on for over two years, forcing doctors to use less effective or more toxic alternatives.
- Levothyroxine - The main treatment for hypothyroidism. Even small changes in dosage can cause fatigue, weight gain, or heart problems. Patients report switching brands and experiencing new side effects.
- Glucagon - Used in emergencies for severe low blood sugar. With rising diabetes rates, demand has surged, but production hasn’t kept up.
It’s not just injectables. ADHD medications like methylphenidate (Ritalin, Concerta) and lisdexamfetamine (Vyvanse) are also in short supply, thanks to a 35% annual increase in prescriptions since 2020. Weight loss drugs like semaglutide (Wegovy, Ozempic) are hitting limits too - not because of manufacturing issues, but because demand has exploded faster than companies can scale production.
Why Are These Drugs So Hard to Find?
The problem isn’t one thing. It’s a chain of failures.First, most of the raw ingredients - called active pharmaceutical ingredients (APIs) - come from just two countries: India (45%) and China (25%). These aren’t just factories. They’re complex, highly regulated plants that must meet U.S. standards. When one fails an FDA inspection - like the one in India that halted cisplatin production - the entire U.S. supply can collapse. And there’s no backup.
Second, generic drugs make up 90% of prescriptions but only 20% of pharmaceutical revenue. Manufacturers make tiny profits - often just 5% to 8% - on these drugs. Why invest in building new plants or upgrading old ones when you can barely cover costs? Brand-name drugs, with 30-40% margins, can afford to keep extra inventory. Generics can’t.
Third, the FDA can’t force companies to make more. They can warn, inspect, and nudge - but they can’t order production. In 2025, FDA Commissioner Robert Califf told Congress the agency prevents about 200 potential shortages each year just by stepping in early. But when a manufacturer decides to quit making a low-profit drug, there’s nothing the government can do to stop it.
Who’s Feeling the Pain?
It’s not just patients. Doctors, nurses, and pharmacists are stretched thin.A 2024 survey by the American Medical Association found that 78% of physicians had to delay treatments because of drug shortages. Over 40% had to switch patients to less effective or riskier alternatives. In one Ohio hospital, pharmacists had to create a points system to decide who got cisplatin - patients with testicular cancer got priority because the drug works best there. Others had to wait.
Pharmacists are spending more than 10 hours a week just tracking down drugs. Nearly two-thirds report medication errors linked to substitutions - like giving the wrong dose because the only available version came in a different strength. A cancer patient in New Mexico told her support group she missed two weeks of chemo because her hospital ran out of doxorubicin. Her tumor grew during that time.
Patients with chronic conditions are the most vulnerable. One mother in Arizona said her son with type 1 diabetes had to go three days without glucagon because the pharmacy couldn’t get it. She kept a spare syringe in her purse, ready to use if he passed out.
What’s Being Done - and What’s Not
Some fixes are happening, but they’re slow and patchy.The FDA launched a new portal in January 2025 where providers can report shortages not yet listed. In three months, it received over 1,200 reports - and acted on 87% of them. That’s progress. But it’s still reactive, not preventive.
Forty-seven states now let pharmacists swap in a similar drug during a shortage. But only 19 let them do it without calling the doctor first. In emergencies, that delay can cost time - and lives.
A few states are trying bold ideas. New York is building a public website to show which drugs are short and which pharmacies still have stock. Hawaii is allowing Medicaid to cover drugs approved in other countries - a move that could bring in alternatives faster. But most hospitals still can’t afford to stockpile extra supplies. Only 28% have a 30-day reserve of critical drugs.
Meanwhile, Congress is debating bills like the End Drug Shortages Act, which would force manufacturers to report supply problems earlier. But without financial incentives to make these low-margin drugs, companies won’t change. And without rebuilding domestic API production, the U.S. will keep depending on foreign plants that can shut down overnight.
What You Can Do Right Now
If you’re on a medication that’s in short supply:- Call your pharmacy early - don’t wait until your last pill is gone.
- Ask if there’s a therapeutically equivalent alternative. Sometimes a different brand or formulation works just as well.
- Check the ASHP Drug Shortages Database online. It’s updated weekly and lists expected resolution dates.
- If you’re on chemotherapy or critical IV therapy, ask your oncologist or care team about their rationing policy. Know your place in line.
- Don’t hoard. Taking extra pills now doesn’t help - it just makes it harder for others to get theirs.
For patients with chronic conditions, keep a written list of your meds, dosages, and the name of your pharmacy. If you have to switch, you’ll need that info fast.
The Bigger Picture
This isn’t going away. The Congressional Budget Office projects drug shortages will stay above 250 through 2027. If new tariffs on Chinese and Indian pharmaceuticals pass, that number could jump to 350 or more.The truth is, we’ve treated drug manufacturing like a commodity - cheap, replaceable, and far away. But when your life depends on a vial of saline or a shot of cisplatin, it’s not a commodity. It’s a lifeline.
Until we invest in domestic production, protect manufacturers who make low-profit drugs, and build real backup systems, these shortages will keep coming. And every time they do, someone’s treatment gets delayed. Someone’s health gets worse. Someone’s family panics.
It’s time to treat medicine like the public good it is - not a line item on a corporate balance sheet.
What are the most common drugs in shortage right now?
As of early 2026, the most common shortages include 5% and 50% Dextrose injections, cisplatin (a chemotherapy drug), vancomycin (an antibiotic), levothyroxine (for thyroid conditions), glucagon (for low blood sugar), and ADHD medications like Vyvanse and Ritalin. These are mostly generic injectables and high-demand oral drugs.
Why are generic drugs more likely to be in short supply than brand-name drugs?
Generic drugs make up 90% of prescriptions but only generate about 20% of pharmaceutical revenue. Manufacturers earn very low profit margins - often just 5% to 8% - so they have little incentive to invest in production upgrades or maintain extra inventory. Brand-name drugs, with 30-40% margins, can afford to keep stockpiles and upgrade facilities.
Can I substitute one drug for another if my medication is out of stock?
In 47 states, pharmacists can substitute a therapeutically equivalent drug during a shortage. But only 19 states allow them to do so without contacting your doctor first. Always ask your pharmacist if a substitution is safe and approved. Never switch on your own.
How do I know if my medication is officially in shortage?
Check the American Society of Health-System Pharmacists (ASHP) Drug Shortages Database. It’s updated weekly and lists active shortages, expected resolution dates, and reasons for the shortage. It’s the most reliable public source.
Are drug shortages getting better or worse?
The number of active shortages has dropped slightly since early 2024, but the underlying causes haven’t changed. Manufacturing issues, overseas dependency, and low profit margins remain. Experts warn that without policy changes - like financial incentives for domestic production - shortages will stay above 250 through at least 2027.
I’ve been a pharmacist for 18 years, and this is the worst it’s ever been. I had a 72-year-old woman cry in my aisle last week because she couldn’t get her levothyroxine-her doctor switched her to a different brand, and now she’s dizzy and exhausted. She didn’t ask for a debate. She just asked if there was any hope. I didn’t have an answer. We’re not just filling prescriptions anymore. We’re holding hands and hoping the next shipment comes in before someone dies.
Let’s be real-this is all a Big Pharma psyop. They’re letting drugs run out so they can push their new $12,000 monthly injectables. You think they care about cisplatin? No. They care about the next ‘miracle’ drug that’ll make you pay for a lifetime supply. And don’t even get me started on the FDA-they’re just the PR arm for the CEOs. Wake up people.
It is imperative to recognize that the structural underinvestment in generic pharmaceutical manufacturing infrastructure constitutes a systemic failure of public health policy. The profit-driven model of pharmaceutical distribution, wherein low-margin essential medications are deprioritized, is not merely inefficient-it is ethically indefensible. One cannot outsource the nation’s lifelines to foreign entities and then be shocked when those lifelines are severed.
So we’re all just supposed to be grateful that someone, somewhere, still makes the saline that keeps us alive? 🤡 Meanwhile, the CEO of that Indian plant is on a yacht in Bali. I’m just here, waiting for my insulin to magically appear. Thanks, capitalism. You’re a real gem.
You think this is bad? Wait till you see what happens when the AI pharmacies take over. They’ll ration your meds based on your credit score. I read it on a blog. They already test your blood for your worthiness. That’s why they’re letting vancomycin disappear-only the ‘deserving’ get it. And guess who’s on the list? Not you. Not me. The rich. Always the rich.
My brother in Lagos was just telling me they have better access to some of these drugs than we do in the U.S.-because Nigeria built local production after years of being ignored. We don’t need to wait for Congress. We need to demand community pharmacies start stockpiling, start sharing, start fighting back. This isn’t just about pills-it’s about dignity. And dignity doesn’t wait for a bill to pass. It starts with one person saying, ‘I won’t let this happen to my neighbor.’
While the systemic deficiencies in the pharmaceutical supply chain are well-documented, it is imperative that stakeholders prioritize the establishment of strategic domestic reserves for essential generic injectables. The current reactive posture of the FDA, though commendable in its early intervention efforts, remains insufficient without legislative mandates for minimum inventory thresholds and public-private partnerships to incentivize production continuity. A national pharmaceutical security framework must be enacted without further delay.